Logo

Expression Pathology

Expression Pathology Changes Name to OncoPlex Diagnostics, Plans 2012 Launch of Lung Cancer Test
Premium

Clinical proteomics firm Expression Pathology has changed its name to OncoPlex Diagnostics and opened a CLIA laboratory in Rockville, Md.

Expression Pathology, MD Anderson Evaluating Technology for Lung Cancer Therapy Selection

NEW YORK (GenomeWeb News) – Expression Pathology today announced a collaboration with the University of Texas MD Anderson Cancer Center for the evaluation of the company's Liquid Tissue SRM technology.

Theranostics Health Launching Alternative to Formalin for Preserving Phosphoproteomic Tissue Samples
Premium

By Adam Bonislawski Theranostics Health has licensed a new fixative developed by researchers at George Mason University that could significantly improve the quality of tissue samples available to proteomic researchers.

Expression Pathology to ID Cancer Protein Biomarkers for Roche's Drug Development Pipeline
Premium

Under the terms of the deal, Expression Pathology will use its Liquid Tissue SRM technology to develop multiplexed quantitative mass spectrometry assays for the detection of cancer signaling pathway proteins in FFPE tissue samples.

Roche Pharma to Use Expression Pathology's Assays

Roche will use the company's multiplexed quantitative assays of cancer signaling pathway proteins.
Dec 10, 2010

Expression Pathology and Flagship Biosciences Partner on Protein Biomarker Work in FFPE Tissue
Premium

Dec 9, 2010

Expression Pathology, Flagship Partner to Offer Translational Biomarker Services

May 7, 2010

Expression Pathology Inks Deal to Use FFPE Technology to Develop Pharmacoproteomic Assays
Premium

May 5, 2010

Expression Pathology in PGx Pact with Toronto Hospitals

Dec 18, 2009

Thermo Fisher's BRIMS Center, Expression Pathology Developing SRM Workflow for Cancer Biomarker Identification
Premium

Dec 18, 2009

Movers & Shakers: Dec 18, 2009
Premium

Dec 18, 2009

Thermo Fisher, Expression Pathology in Proteomic Alliance

Nov 20, 2009

Mayo Clinic Licenses Expression Pathology Technology for MS-based Amyloidosis Assay
Premium

Nov 18, 2009

Mayo Clinic Licenses Expression Pathology IP

Apr 23, 2009

Expression Pathology Nabs $6.5M Investment from Abraxis to Develop Cancer Drug-Response Dxs
Premium

Apr 21, 2009

Expression Pathology Gets $6.5M Investment from Abraxis

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.